Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
NEW YORK, May 05, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunoCellular Therapeutics, Ltd. (NYSE MKT:IMUC) who purchased shares between May 1, 2012 and December 11, 2013. The action, which was filed in the United States District Court for the Central District of California, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; (2) as a result of this scheme, the market was led to believe that ImmunoCellular's clinical studies for its product candidate ICT-107 was going well and the Company's share price was artificially inflated.
On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, that had engaged in stock promotion schemes.
Shareholders have until June 30, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/immunocellular-therapeutics-ltd?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
